Modulationof EGFR/HER1 signaling by specific receptor function (kinase domain) inhibitorsor neutralizing antibodies against specific EGFR1 ligands (e.g., HB-EGFantibodies) can be an attractive therapeutic modality (particularly in the contextof neoplastic diseases associated with elevated TGF-β1 levels). The gene discussed is EGFR; the disease is neoplasm.